⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 4, 2024Open Access

Supplementary Figure S1 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Chun‐Ping Chang Teng‐Kuang Yeh Chiung‐Tong Chen Wan-Ping Wang Yen-Ting Chen Chia‐Hua Tsai Yan-Fu Chen Yi‐Yu Ke Jing-Ya Wang Ching-Ping Chen Tsung-Chih Hsieh Mine-Hsine Wu Chen‐Lung Huang Ya-Ping Chen Hong Zhuang Ya‐Hui Chi

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S1. Discovery and synthesis of 6K465. (A) Synthesis of pyrimidine derivatives Cmpd-T and 6K465 which possess a six-membered ring amine. (B) Western blot analysis for the expression of c-MYC and N-MYC respectively in NCI-H82 and SK-N-BE(2) cells treated with 1.0 or 5.0 uM of the indicated compounds for 2 hr.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chang et al. (2024) studied this question.

synapsesocial.com/papers/68e664bab6db6435875f16f2 https://doi.org/10.1158/1535-7163.25964791

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
2Supplementary Figure S2 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
3Supplementary Figure S2 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
4Data from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
5Supplementary Figure S7 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024

Supplementary Figure S7 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
Supplementary Figure S4 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024